Literature DB >> 25584001

Erlotinib versus docetaxel as second- or third-line therapy in patients with advanced non-small-cell lung cancer in the era of personalized medicine.

Bivas Biswas1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25584001     DOI： 10.1200/JCO.2014.57.5621

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  3 in total

Review 1.  Recent developments in receptor tyrosine kinases targeted anticancer therapy.

Authors:  Samir H Raval; Ratn D Singh; Dilip V Joshi; Hitesh B Patel; Shailesh K Mody
Journal:  Vet World       Date:  2016-01-29

2.  Geographic Variations and Time Trends in Cancer Treatments in Taiwan.

Authors:  Jason C Hsu; Sheng-Mao Chang; Christine Y Lu
Journal:  BMC Public Health       Date:  2017-08-02       Impact factor: 3.295

3.  Systematic review and meta-analysis of third-line salvage therapy for the treatment of advanced non-small-cell lung cancer: A meta-analysis of randomized controlled trials.

Authors:  Nan Zhang; Nan Guo; Liang Tian; Zhigang Miao
Journal:  Oncotarget       Date:  2018-03-23
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.